Skip to main content

Table 2 Summary of multivariable regression results

From: Contribution of BDNF and DRD2 genetic polymorphisms to continued opioid use in patients receiving methadone treatment for opioid use disorder: an observational study

Continued opioid use

OR

95 % CI

p value

Age: year

1.00

0.966, 1.038

0.928

Sex: male

0.64

0.349, 1.178

0.152

Ethnicity: European

1.83

0.715, 4.697

0.207

Age of initial opioid use: year

1.02

0.986, 1.060

0.235

Methadone dose: milligram

0.99

0.983, 0.998

0.016

Duration on treatment: month

1.00

0.987, 1.005

0.364

Total number of opioid screens

1.01

0.997, 1.024

0.148

BDNF rs6265: allele (A)

1.37

0.792, 2.371

0.260

DRD2 rs1799978: allele (G)

1.28

0.511, 3.182

0.603

  1. LR χ2(7) = 20.23, Prob > χ2 = 0.0165, Psuedo R2 = 0.0728, Log likelihood = −128.822
  2. BDNF brain-derived neurotrophic factor, DRD2 dopamine receptor D2, OR odds ratio, CI confidence interval